Conditions: Elevated High-sensitivity C-Reactive Protein (hsCRP)
Keywords: Primary prevention Cardiovascular disease Statin therapy C-reactive protein
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 17802
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of major cardiovascular events.

Detailed description:
AstraZeneca announced it has decided to stop the CRESTOR JUPITER clinical study early based on a recommendation from an Independent Data Monitoring Board and the JUPITER Steering Committee, which met on March 29, 2008. The study will be stopped early because there is unequivocal evidence of a reduction in cardiovascular morbidity and mortality amongst patients who received CRESTOR when compared to placebo.

Arms:
arm 1: Rosuvastatin 20 mg once daily arm 2: Placebo once daily

Interventions: intervention 1: Rosuvastatin intervention 2: Placebo
Intervention descriptions: intervention 1: Oral intervention 2: Oral

Protocol document: